Omeros (OMER) Income from Non-Controlling Interests (2023)

Omeros (OMER) reported Income from Non-Controlling Interests of $300000.0 for Q4 2023.

Omeros (OMER) Income from Non-Controlling Interests (2023) Analysis & Trends

Omeros (OMER) has 1 years of Income from Non-Controlling Interests data on file, last reported at $300000.0 in Q4 2023.

For the quarter ending Q4 2023, Income from Non-Controlling Interests changed N/A year-over-year to $300000.0; the trailing twelve-month figure through Dec 2023 stood at $300000.0 (changed N/A YoY), and the FY2023 full-year result was $300000.0, changed N/A from the prior year.
Income from Non-Controlling Interests was little changed at $300000.0 in Q4 2023.
In the past five years, Income from Non-Controlling Interests ranged from a high of $300000.0 in Q4 2023 to a low of $300000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inc. Minority (Qtr)
1	Oculis Holding AG	67,583.17 Bn	67,582.89 Bn	-	-
2	Nanobiotix	1,947.22 Bn	1,947.15 Bn	-	-
3	Akari Therapeutics	1,132.35 Bn	1,132.35 Bn	-	-
4	BeOne Medicines	473.21 Bn	468.42 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	123.29 Bn	116.04 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	70.05 Bn	61.29 Bn	3.31 Bn	-
7	Belite Bio	63.09 Bn	63.09 Bn	-	-
8	Argenx Se	56.63 Bn	51.45 Bn	1.41 Bn	-
9	Revolution Medicines	37.79 Bn	37.79 Bn	-	-
10	Omeros	783.18 Mn	783.18 Mn	9.31 Mn	-

Download Data

Date	Value
Dec 31, 2023	300,000.00